Simufilam is a therapeutic approach or intervention being investigated for neurodegenerative diseases. This page reviews the scientific rationale, preclinical and clinical evidence, dosing considerations, and current status of research.
Simufilam (formerly PTI-125) was an investigational oral drug candidate developed by Cassava Sciences for the treatment of Alzheimer's disease. It was designed as a small molecule amyloid-beta (Aβ) oligomer antagonist that targets filamin A to prevent Aβ42 from binding to α7 nicotinic acetylcholine receptors. [1]
Simufilam's mechanism centers on binding to filamin A (FLNA), a large intracellular scaffolding protein that plays a critical role in maintaining neuronal architecture. In Alzheimer's disease, Aβ42 oligomers were proposed to induce aberrant filamin A linkages that disrupt normal cellular signaling. [2]
The proposed mechanism involves: [3]
This mechanism was distinct from other Alzheimer's drug candidates that target amyloid through antibody-mediated clearance or beta-secretase inhibition. [4]
Preclinical studies demonstrated that Simufilam: [5]
Phase 2a (2019) - NCT03135487 [6]
Phase 2b (2020) - 28-day dosing phase [7]
ReThink-ALZ (NCT04693524) [8]
ReFocus-ALZ [9]
Following the Phase 3 failures, Cassava Sciences discontinued their Alzheimer's program. [10]
Across clinical trials, Simufilam was generally well-tolerated: [11]
The Simufilam program faced significant scrutiny: [12]
Despite the negative trial results, Simufilam represents an important case study in Alzheimer's drug development:
Confirm Mechanism of Action
Biomarker Development
Combination Therapy Development
Phase 3 Trial Design (Proposed)
Wang et al. Simufilam Reverses Aberrant Receptor Interactions of Filamin A in Alzheimer's Disease (2023). 2023. ↩︎
Comment on Wang et al. Simufilam Reverses Aberrant Receptor Interactions (2024). 2024. ↩︎
Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development (2023). 2023. ↩︎
Simufilam in Alzheimer's Disease: Assessment of Efficacy in Human Neuronal Cell Culture (2024). 2024. ↩︎
Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in AD patient lymphocytes (2023). 2023. ↩︎
Phase 3 randomized clinical trials of simufilam in mild-to-moderate Alzheimer's disease (2024). 2024. ↩︎
PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients (2020). 2020. ↩︎
Cassava Sciences Phase 3 Trial Information - ClinicalTrials.gov NCT04693524. ↩︎
Cassava Sciences Phase 2 Trial Information - ClinicalTrials.gov NCT03135487. ↩︎
SEC Settlement Announcement - Cassava Sciences (0M). 2024. ↩︎